Production (Stage)
Neuphoria Therapeutics Inc.
NEUP
$6.87
-$0.28-3.92%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 15.00M | 662.70K | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -48.40K | -- |
| Total Revenue | 15.00M | 662.70K | -- | -48.40K | -- |
| Cost of Revenue | 1.62M | 1.74M | 1.90M | -2.58M | 1.20M |
| Gross Profit | 13.38M | -1.07M | -1.90M | 2.53M | -1.20M |
| SG&A Expenses | 1.41M | 2.63M | 1.67M | 2.18M | 1.20M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.03M | 4.06M | 3.57M | 4.27M | 2.39M |
| Operating Income | 11.97M | -3.40M | -3.57M | -4.31M | -2.39M |
| Income Before Tax | 11.18M | -1.93M | -937.00K | -2.63M | -2.76M |
| Income Tax Expenses | -81.20K | 11.60K | -132.20K | -8.10K | 16.40K |
| Earnings from Continuing Operations | 11.26M | -1.94M | -804.80K | -2.62M | -2.78M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.26M | -1.94M | -804.80K | -2.62M | -2.78M |
| EBIT | 11.97M | -3.40M | -3.57M | -4.31M | -2.39M |
| EBITDA | 12.14M | -3.23M | -3.40M | -4.20M | -2.23M |
| EPS Basic | 6.55 | -1.23 | 0.00 | 0.00 | -2.83 |
| Normalized Basic EPS | 4.07 | -0.77 | 0.00 | 0.00 | -1.76 |
| EPS Diluted | 6.55 | -1.23 | 0.00 | 0.00 | -2.83 |
| Normalized Diluted EPS | 4.07 | -0.77 | 0.00 | 0.00 | -1.76 |
| Average Basic Shares Outstanding | 1.72M | 1.58M | 2.81B | 1.89B | 981.00K |
| Average Diluted Shares Outstanding | 1.72M | 1.58M | 2.81B | 1.89B | 981.00K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |